Heparin, Gore Viabahn VBX, Balloon Expandable Endoprosthesis, for the following Reference numbers...

FDA Device Recall #Z-2946-2024 — Class II — July 1, 2024

Recall Summary

Recall Number Z-2946-2024
Classification Class II — Moderate risk
Date Initiated July 1, 2024
Status Ongoing
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm W L Gore & Associates, Inc.
Location Flagstaff, AZ
Product Type Devices
Quantity 100 units

Product Description

Heparin, Gore Viabahn VBX, Balloon Expandable Endoprosthesis, for the following Reference numbers: United States: BXB055902C, BXB063902C, BXB065902C, BXB067902C, BXB073902C, BXB075902C, BXB077902C, BXB083902C, BXB085902C, BXB087902C, BXB093902C, BXB095902C, BXB097902C *For Clinical use.

Reason for Recall

Due to packaging defects, sterility assurance and heparin activity may be compromised.

Distribution Pattern

Worldwide - US Nationwide distribution including in the states of AK, AL, AR, AZ, CA, CO, CT, DC, DE, FL, GA, HI, IA, ID, IL, IN, KS, KY, LA, MA, MD, ME, MI, MN, MO, MS, MT, NC, ND, NE, NJ, NV, NY, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VA, VT, WA, WI, WV, WY and the country of Japan.

Lot / Code Information

Lot Serial Number/UDI: 27342032/00733132658053; 27342035/00733132658053; 27342038/00733132658053; 27342047/00733132657926; 27342078/00733132657940; 27342079/00733132657940; 27342102/00733132657957; 27342104/00733132657957; 27342108/00733132657957; 27342253/00733132657964; 27342255/00733132657964; 27342256/00733132657964; 27342257/00733132657964; 27342258/00733132657964; 27342259/00733132657964; 27342260/00733132657964; 27342261/00733132657964; 27342262/00733132657964; 27342263/00733132657964; 27342264/00733132657971; 27342266/00733132657971; 27342267/00733132657971; 27342268/00733132657971; 27342269/00733132657971; 27342270/00733132657971; 27342290/00733132657988; 27342333/00733132657995; 27342334/00733132657995; 27342335/00733132657995; 27342336/00733132657995; 27342337/00733132657995; 27342338/00733132657995; 27342339/00733132657995; 27342340/00733132657995; 27342341/00733132657995; 27342342/00733132657995; 27342343/00733132657995; 27342344/00733132657995; 27342345/00733132657995; 27342346/00733132657995; 27342347/00733132657995; 27342349/00733132657995; 27342350/00733132657995; 27342352/00733132657995; 27342403/00733132658008; 27342535/00733132658015; 27342536/00733132658015; 27342571/00733132658022; 27342572/00733132658022; 27342585/00733132658039; 27342586/00733132658039; 27342587/00733132658039; 27342591/00733132658039; 27342624/00733132658046; 27342626/00733132658046; 27342627/00733132658046; 27342628/00733132658046; 27399807/00733132658053; 27399808/00733132658053; 27399814/00733132658053; 27399815/00733132658053; 27399816/00733132658053; 27399883/00733132657957; 27399884/00733132657957; 27399886/00733132657957; 27399894/00733132657964; 27399895/00733132657964; 27399896/00733132657964; 27399897/00733132657964; 27399898/00733132657964; 27399920/00733132657971; 27399921/00733132657971; 27399922/00733132657971; 27399923/00733132657971; 27399924/00733132657971; 27399925/00733132657971; 27399929/00733132657988; 27399933/00733132657988; 27399934/00733132657988; 27399935/00733132657988; 27399936/00733132657988; 27399937/00733132657988; 27399938/00733132657988; 27399939/00733132657988; 27399942/00733132657988; 27400054/00733132658015 27400056/ 00733132658015 27400073/ 00733132658022 27400077/ 00733132658039 27400078/ 00733132658039 27400079/ 00733132658039 27400084/ 00733132658039 27400085/ 00733132658039 27400103/ 00733132658046 27400104/ 00733132658046 27400105/ 00733132658046 27400110/ 00733132658046 27400111/ 00733132658046 27461768/ 00733132658046 27461769/ 00733132658046

Other Recalls from W L Gore & Associates, Inc.

Recall # Classification Product Date
Z-0036-2026 Class II GORE ACUSEAL Vascular Graft, REF: ECH050020J, E... Aug 26, 2025
Z-2945-2024 Class II Heparin, Gore Viabahn VBX, Balloon Expandable E... Jul 1, 2024
Z-1048-2023 Class II GORE CARDIOFORM Septal Occluder, REF: GSX0030A Dec 14, 2022
Z-0136-2023 Class II GORE CARDIOFORM ASD Occluder. cardiovascular im... Sep 21, 2022
Z-0077-2022 Class II Heparin, GORE VIABAHN VBX, BALLOON EXPANDABLE E... Sep 7, 2021

Frequently Asked Questions

Sterility recalls for medical devices vary in severity. If you have already had a procedure using a potentially non-sterile device, contact your healthcare provider immediately — you may need monitoring for signs of infection. Symptoms to watch for include fever, redness or swelling at the surgical site, unusual pain, or discharge. For devices that have not yet been used, they should be quarantined and returned to the manufacturer per the recall notice. Non-sterile implants can cause serious infections; early detection and treatment are critical.

Class I recalls indicate a reasonable probability of serious adverse health consequences or death from the defect. Class II recalls involve products that may cause temporary or medically reversible adverse health consequences, or where serious consequences are remote. Class III recalls cover products not likely to cause any adverse health consequences, typically involving technical regulatory violations. The classification guides urgency — Class I recalls require immediate action, while Class III may simply involve returning a product or acknowledging a labeling change. Always read the specific recall notice for recommended patient actions.

Report problems with medical devices to the FDA through MedWatch at 1-800-FDA-1088 or online at FDA.gov/safety/medwatch. Healthcare facilities are required by law to report device-related serious injuries and deaths. Patients and consumers can also report voluntarily. Include the device name, manufacturer, model number, and a description of the problem and any patient outcome. Reports from patients and clinicians help the FDA identify emerging safety signals and may trigger investigations that lead to recalls of dangerous devices.

What Should You Do?

Stop using this device if you are affected by this recall. Contact your healthcare provider and the manufacturer immediately for guidance. Report adverse events to FDA MedWatch.